Repligen Corporation et al v. Bristol-Myers Squibb Company, No. 2:06-cv-00004 (E.D. Tex. July 20, 2006)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Plaintiffs Repligen Corporation (hereinafter “Repligen”) and The Regents of the University of Michigan (hereinafter “Regents”) (collectively “Plaintiffs”) sued Defendant Bristol-Myers Squibb Company, (hereinafter “Bristol-Myers”) for allegedly infringing United States Patent No. 6,685,941 (hereinafter “the ’941 patent”). The ‘941 patent involves the use of a compound called “CTLA4-Ig” to treat autoimmune diseases. Repligen moves this Court to transfer venue to the Eastern District of Michigan.